Literature DB >> 11474279

Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer.

M L Wang1, W K Yung, M E Royce, D F Schomer, R L Theriault.   

Abstract

We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine. The metastases had progressed and Karnofsky performance status deteriorated despite whole brain irradiation, hormonal treatment, and systemic chemotherapy that included 5-fluorouracil (5-FU). In contrast, 2 months of treatment with oral capecitabine produced a partial response, documented by lesion size on magnetic resonance imaging and an improvement in performance status; both measures continued to improve during 11 months of capecitabine treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474279     DOI: 10.1097/00000421-200108000-00026

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  17 in total

Review 1.  Treatment of brain metastases: chemotherapy.

Authors:  Sean A Grimm
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.

Authors:  Lisa R Rogers; Sandra E Remer; Sheela Tejwani
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

3.  Systemic high-dose intravenous methotrexate for central nervous system metastases.

Authors:  Andrew B Lassman; Lauren E Abrey; Gaurav D Shah; Gaurav G Shah; Katherine S Panageas; Martin Begemann; Mark G Malkin; Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2006-07       Impact factor: 4.130

Review 4.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

5.  Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).

Authors:  Jessica M Grunda; L Burton Nabors; Cheryl A Palmer; David C Chhieng; Adam Steg; Tom Mikkelsen; Robert B Diasio; Kui Zhang; David Allison; William E Grizzle; Wenquan Wang; G Yancey Gillespie; Martin R Johnson
Journal:  J Neurooncol       Date:  2006-06-14       Impact factor: 4.130

6.  Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.

Authors:  Jessica M Grunda; John Fiveash; Cheryl A Palmer; Alan Cantor; Hassan M Fathallah-Shaykh; L Burt Nabors; Martin R Johnson
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

Review 7.  Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

Authors:  Marc C Chamberlain; Christina S Baik; Vijayakrishna K Gadi; Shailender Bhatia; Laura Q M Chow
Journal:  Neuro Oncol       Date:  2017-01       Impact factor: 12.300

8.  Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

Authors:  Christos Christodoulou; Anna Kalogera-Fountzila; Vasilios Karavasilis; George Kouvatseas; Christos N Papandreou; Epaminontas Samantas; Kalliopi Varaki; Georgios Papadopoulos; Mattheos Bobos; Grigorios Rallis; Evangelia Razis; Athina Goudopoulou; Konstantine T Kalogeras; Konstantinos N Syrigos; George Fountzilas
Journal:  J Neurooncol       Date:  2017-07-07       Impact factor: 4.130

Review 9.  Systemic therapy of brain metastases.

Authors:  Harry C Brastianos; Daniel P Cahill; Priscilla K Brastianos
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

10.  Capecitabine therapy of central nervous system metastases from breast cancer.

Authors:  Meltem Ekenel; Adilia M Hormigo; Scott Peak; Lisa M Deangelis; Lauren E Abrey
Journal:  J Neurooncol       Date:  2007-07-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.